99 related articles for article (PubMed ID: 8470175)
1. Platelet activating factor mediates systemic circulatory collapse after temporary hepatic inflow occlusion.
Fukuoka T; Nakajima Y; Horikawa M; Aomatsu Y; Yoshimura A; Ueno M; Ko S; Nakano H
Transplant Proc; 1993 Apr; 25(2):1809-10. PubMed ID: 8470175
[No Abstract] [Full Text] [Related]
2. [An experimental study on shock after temporary hepatic inflow occlusion and platelet activating factor (PAF)].
Fukuoka T
Nihon Geka Gakkai Zasshi; 1990 Oct; 91(10):1596-602. PubMed ID: 2263243
[TBL] [Abstract][Full Text] [Related]
3. Effect of a platelet activating factor antagonist (CV6209) on shock caused by temporary hepatic inflow occlusion.
Fukuoka T; Nakajima Y; Matsumoto M; Segawa M; Kanehiro H; Hisanaga M; Wada T; Nakano H
Life Sci; 1990; 47(6):565-70. PubMed ID: 2402181
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of platelet-activating factor antagonist on hepatic energy metabolism following transient hepatic inflow occlusion in rabbits.
Takada Y; Shimahara Y; Yamaguchi T; Nishizawa F; Mori K; Yamaoka Y; Ozawa K
Circ Shock; 1992 Oct; 38(2):130-7. PubMed ID: 1423921
[TBL] [Abstract][Full Text] [Related]
5. Role of platelet-activating factor in hepatectomy with Pringle's maneuver.
Gu M; Takada Y; Fukunaga K; Ishiguro S; Taniguchi H; Seino K; Yuzawa K; Otsuka M; Todoroki T; Fukao K
J Surg Res; 2001 Apr; 96(2):233-8. PubMed ID: 11266278
[TBL] [Abstract][Full Text] [Related]
6. ABT-299, a potent antagonist of platelet activating factor.
Summers JB; Albert DH; Davidsen SK; Conway RG; Holms JH; Magoc TJ; Luo G; Tapang P; Rhein DA; Carter GW
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():475-7. PubMed ID: 7732895
[No Abstract] [Full Text] [Related]
7. Platelet activating factor (PAF) increases leukocyte adhesion but does not alter vessel diameter in the rat mesenteric microcirculation.
Smalley DM; Wood JG; Childs EW; Frank LL; Cheung LY
Microvasc Res; 1998 Nov; 56(3):271-6. PubMed ID: 9828165
[No Abstract] [Full Text] [Related]
8. Tolerance limit of rats to normothermic hepatic inflow occlusion under portal blood bypass.
Dong JH; He XD; Li K; Duan HC; Peng ZM; Cai JX
Hepatobiliary Pancreat Dis Int; 2002 Feb; 1(1):57-62. PubMed ID: 14607624
[TBL] [Abstract][Full Text] [Related]
9. Colored microsphere technique as a new method for quantitative-multiple estimation of regional hepatic and portal blood flow.
Bauer R; Walter B; Würker E; Kluge H; Zwiener U
Exp Toxicol Pathol; 1996 Jul; 48(5):415-20. PubMed ID: 8765686
[TBL] [Abstract][Full Text] [Related]
10. Hepatic microvascular pressure during anaphylactic shock in anesthetized rats.
Takano H; Shibamoto T; Zhang W; Kurata Y; Toga H
Microvasc Res; 2009 Sep; 78(2):169-73. PubMed ID: 19573539
[TBL] [Abstract][Full Text] [Related]
11. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.
Deibert P; Schumacher YO; Ruecker G; Opitz OG; Blum HE; Rössle M; Kreisel W
Aliment Pharmacol Ther; 2006 Jan; 23(1):121-8. PubMed ID: 16393289
[TBL] [Abstract][Full Text] [Related]
12. Vascular actions of the prostacyclin receptor antagonist BAY 73-1449 in the portal hypertensive rat.
Bexis S; McCormick PA; Docherty JR
Eur J Pharmacol; 2008 Aug; 590(1-3):322-6. PubMed ID: 18603238
[TBL] [Abstract][Full Text] [Related]
13. Bile duct exclusion from selective vascular inflow occlusion in rat liver: role of ischemic preconditioning and N-acetylcysteine on hepatic reperfusion injury.
Montero EF; Quireze C; d'Oliveira DM
Transplant Proc; 2005; 37(1):425-7. PubMed ID: 15808665
[TBL] [Abstract][Full Text] [Related]
14. PAF, rather than histamine, participates in mouse anaphylactic hypotension.
Shibamoto T; Liu W; Cui S; Zhang W; Takano H; Kurata Y
Pharmacology; 2008; 82(2):114-20. PubMed ID: 18583921
[TBL] [Abstract][Full Text] [Related]
15. Significance of platelet-activating factor in mesenteric ischemia-reperfusion.
Filep J; Braquet P; Mózes T
Lipids; 1991 Dec; 26(12):1336-9. PubMed ID: 1819728
[TBL] [Abstract][Full Text] [Related]
16. [Effect of a platelet activating factor (PAF) antagonist on the hepatic afferent vascular occlusion].
Fukuoka T; Nakajima Y; Matsumoto M; Nakano H; Shiratori T
Nihon Geka Gakkai Zasshi; 1988 May; 89(5):788. PubMed ID: 3412312
[No Abstract] [Full Text] [Related]
17. The effects of platelet activating factor on isolated rat hearts.
Pugsley MK; Salari H; Beatch GN; Walker MJ
Proc West Pharmacol Soc; 1990; 33():129-32. PubMed ID: 2274523
[No Abstract] [Full Text] [Related]
18. The effect of hepatic blood inflow occlusion on hepatic cancer treated with diode-laser thermocoagulation.
Hong DF; Li SY; Tong LM; Chen B; Peng SY
J Zhejiang Univ Sci B; 2005 Apr; 6(4):232-5. PubMed ID: 15754418
[TBL] [Abstract][Full Text] [Related]
19. Platelet-activating factor as a vasodepressive mediator of liver ischemia.
Fukuoka T; Nakajima Y; Nakano H
Transplant Proc; 1993 Dec; 25(6):3225-7. PubMed ID: 8266523
[No Abstract] [Full Text] [Related]
20. Role of thromboxane A2 and platelet activating factor in early haemodynamic response to lipopolysaccharide in rats.
Bocheński J; Chłopicki S; Gryglewski RJ
J Physiol Pharmacol; 1999 Jun; 50(2):287-97. PubMed ID: 10424723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
